Embecta Corp. (EMBC) – What Are Investment Firms Thinking About This Stock?

Shares of Embecta Corp. (NASDAQ:EMBC) have earned an average recommendation of “Reduce” from the five brokerages that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and three have given a hold rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $11.00.

A number of brokerages have recently issued reports on EMBC. Zacks Research raised Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th. Weiss Ratings upgraded Embecta from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, October 9th.

Embecta Stock Down 1.0%

NASDAQ EMBC opened at $6.21 on Thursday. The company has a market capitalization of $351.86 million, a P/E ratio of 3.07 and a beta of 0.84. Embecta has a 12-month low of $2.77 and a 12-month high of $14.91. The firm has a 50-day moving average price of $5.48 and a two-hundred day moving average price of $5.00.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings results on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.29. The company had revenue of $271.70 million for the quarter, compared to the consensus estimate of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The firm’s quarterly revenue was down 8.1% compared to the same quarter last year. During the same period last year, the company posted $1.12 EPS. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Equities analysts expect that Embecta will post 1.84 EPS for the current year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th were given a $0.01 dividend. The ex-dividend date of this dividend was Thursday, August 27th. This represents a $0.04 annualized dividend and a yield of 0.6%. Embecta’s payout ratio is currently 2.70%.

Insiders Place Their Bets

In other Embecta news, insider Jeffrey Mann acquired 20,000 shares of Embecta stock in a transaction on Wednesday, August 12th. The stock was purchased at an average price of $4.99 per share, for a total transaction of $99,800.00. Following the purchase, the insider directly owned 262,915 shares of the company’s stock, valued at $1,311,945.85. This trade represents a 8.23% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Jacob Elguicze bought 20,000 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average cost of $4.67 per share, with a total value of $93,400.00. Following the completion of the transaction, the chief financial officer owned 309,139 shares in the company, valued at approximately $1,443,679.13. The trade was a 6.92% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 70,000 shares of company stock worth $334,200 over the last 90 days. Company insiders own 1.30% of the company’s stock.

Institutional Trading of Embecta

A number of large investors have recently added to or reduced their stakes in the stock. River Road Asset Management LLC lifted its stake in Embecta by 5.3% in the fourth quarter. River Road Asset Management LLC now owns 3,416,401 shares of the company’s stock valued at $40,587,000 after purchasing an additional 171,194 shares during the last quarter. SG Americas Securities LLC grew its holdings in Embecta by 138.4% during the first quarter. SG Americas Securities LLC now owns 1,038,948 shares of the company’s stock valued at $9,184,000 after purchasing an additional 603,106 shares during the period. Dimensional Fund Advisors LP grew its holdings in Embecta by 7.8% during the first quarter. Dimensional Fund Advisors LP now owns 934,210 shares of the company’s stock valued at $8,258,000 after purchasing an additional 67,374 shares during the period. Bank of New York Mellon Corp increased its position in Embecta by 1.3% in the first quarter. Bank of New York Mellon Corp now owns 823,787 shares of the company’s stock worth $7,282,000 after buying an additional 10,468 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in Embecta in the first quarter worth $7,013,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Embecta Company Profile

Embecta Corporation (NASDAQ: EMBC) is a global diabetes-care company that develops, manufactures and markets medical devices used to deliver insulin and monitor blood glucose. Its product portfolio includes insulin pen needles, insulin syringes, safety-engineered injection devices, lancets and related diabetes-management products.

The company serves people with diabetes, health care professionals, hospitals and other health care providers through commercial operations and distribution partners in markets around the world.